Alzamend Neuro (ALZN) 10-K 29 Jul 21 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Apr. 30, 2021	Jul. 20, 2021	Oct. 31, 2020
Cover [Abstract]
Entity Registrant Name	Alzamend Neuro, Inc.
Entity Central Index Key	0001677077
Document Type	10-K
Entity File Number	001-40483
Document Period End Date	Apr. 30, 2021
Amendment Flag	false
Current Fiscal Year End Date	--04-30
Entity Well Known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Reporting Status Current	No
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	DE
Entity Filer Category	Non-accelerated Filer
Emerging Growth Company	true
Entity Ex Transition Period	false
Entity a Small Business	true
Entity Shell Company	false
Entity Public Float			$ 745,100,000
Entity Common Stock, Shares Outstanding		85,304,525
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021

Balance Sheets

Balance Sheets - USD ($)	Apr. 30, 2021	Apr. 30, 2020
CURRENT ASSETS
Cash	$ 1,929,270	$ 90,285
Note receivable, related party, net		100,915
Prepaid expenses and other current assets	983,320	1,622,815
TOTAL CURRENT ASSETS	2,912,590	1,814,015
TOTAL ASSETS	2,912,590	1,814,015
CURRENT LIABILITIES
Accounts payable and accrued liabilities	503,591	929,639
Related party payable	60,749	62,667
Convertible notes, net	335,303
TOTAL CURRENT LIABILITIES	899,643	992,306
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Convertible Preferred stock, $0.0001 par value: 10,000,000 shares authorized; Series A Convertible Preferred Stock, $0.0001 stated value per share, 1,360,000 shares designated; 750,000 shares issued and outstanding as of April 30, 2021 and 2020, respectively	75	75
Common stock, $0.0001 par value: 300,000,000 shares authorized; 67,429,525 and 64,762,858 shares issued and outstanding as of April 30, 2021 and 2020, respectively	6,743	6,476
Additional paid-in capital	33,721,860	27,584,227
Note receivable for common stock - related party	(14,883,295)	(14,983,200)
Accumulated deficit	(16,832,436)	(11,785,869)
TOTAL STOCKHOLDERS' EQUITY	2,012,947	821,709
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 2,912,590	$ 1,814,015

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Apr. 30, 2021	Apr. 30, 2020
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized	300,000,000	300,000,000
Common stock, issued	67,429,525	64,762,858
Common stock, outstanding	67,429,525	64,762,858
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized	8,640,000
Preferred stock, designated	1,360,000	1,360,000
Preferred stock, issued	750,000	750,000
Preferred stock, outstanding	750,000	750,000

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Apr. 30, 2021	Apr. 30, 2020
OPERATING EXPENSES
Research and development	$ 1,310,716	$ 1,069,418
General and administrative	3,641,172	3,354,743
Total operating expenses	4,951,888	4,424,161
Loss from operations	(4,951,888)	(4,424,161)
OTHER INCOME (EXPENSE), NET
Gain on extinguishment of debt	62,418
Interest expense	(142,421)
Interest expense - related party	(16,382)
Interest income - related party	1,706	13,925
Total other income (expense), net	(94,679)	13,925
NET LOSS	$ (5,046,567)	$ (4,410,236)
Basic and diluted net loss per common share (in dollars per share)	$ (0.07)	$ (0.06)
Basic and diluted weighted average common shares outstanding (in shares)	72,650,073	71,253,580

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Apr. 30, 2021	Apr. 30, 2020
Cash flows from operating activities:
Net loss	$ (5,046,567)	$ (4,410,236)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest expense-debt discount amortization	124,046
Interest expense - debt discount, related party	14,300
Gain on extinguishment of debt	(62,418)
Stock-based compensation to employees and consultants	2,032,359	1,801,516
Non-cash consulting expense from issuance of common stock	378,704	453,724
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	260,791	(15,764)
Accounts payable and accrued expenses	(413,242)	(175,030)
Net cash used in operating activities	(2,712,027)	(2,345,790)
Cash flows from investing activities:
Proceeds from repayments of notes receivable - related party	100,915	105,000
Net cash provided by investing activities	100,915	105,000
Cash flows from financing activities:
Proceeds from the issuance of common stock and warrants, net	2,100,000	2,288,335
Proceeds from short-term advances, related party	1,850,000	(16,666)
Proceeds from convertible note payable, related party	50,000
Payments of related party payable	(1,918)
Proceeds from note payable	62,110
Proceeds from note receivable for common stock - related party	99,905	16,800
Proceeds from convertible note payable	290,000
Net cash provided by financing activities	4,450,097	2,288,469
Net increase in cash	1,838,985	47,679
Cash at beginning of period	90,285	42,606
Cash at end of period	1,929,270	90,285
Non-cash financing activities:
Accrued interest payable, related party, satisfied with the issuance of common stock	12,498
Issuance of common stock in payment of short-term advances, related party	1,850,000
Issuance of common stock in payment of convertible notes payable, related party	50,000
Fair value of warrants issued in connection with convertible notes payable	91,241
Fair value of warrants issued in connection with convertible notes payable, related party	$ 14,300

Statements of Changes in Stockh

Statements of Changes in Stockholders' Equity - USD ($)	Series A Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Note Receivable for Common Stock - Related Party [Member]	Accumulated Deficit [Member]	Total
Balance, at beginning at Apr. 30, 2019	$ 75	$ 6,188	$ 22,686,285	$ (15,000,000)	$ (7,375,633)	$ 316,915
Balance, at beginning (in shares) at Apr. 30, 2019	750,000	61,878,465
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock and warrants		$ 228	2,288,107			2,288,335
Issuance of common stock and warrants (in shares)		2,284,393
Stock-based compensation to employees and consultants			1,801,516			1,801,516
Proceeds from note receivable - related party for common stock				16,800		16,800
Issuance of common stock for services		$ 60	808,319			808,379
Issuance of common stock for services (in shares)		600,000
Net loss					(4,410,236)	(4,410,236)
Balance, at end at Apr. 30, 2020	$ 75	$ 6,476	27,584,227	(14,983,200)	(11,785,869)	821,709
Balance, at end (in shares) at Apr. 30, 2020	750,000	64,762,858
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, related party		$ 267	3,999,733			4,000,000
Issuance of common stock, related party (in shares)		2,666,667
Stock-based compensation to employees and consultants			2,032,359			2,032,359
Proceeds from note receivable - related party for common stock				99,905		99,905
Fair value of warrants issued in connection with convertible notes			91,241			91,241
Fair value of warrants issued in connection with convertible notes - related party			14,300			14,300
Net loss					(5,046,567)	(5,046,567)
Balance, at end at Apr. 30, 2021	$ 75	$ 6,743	$ 33,721,860	$ (14,883,295)	$ (16,832,436)	$ 2,012,947
Balance, at end (in shares) at Apr. 30, 2021	750,000	67,429,525

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	12 Months Ended
	Apr. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	1. DESCRIPTION OF BUSINESS Alzamend Neuro, Inc. (the “Company” or “Alzamend”), is a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. The Company’s primary focus is Alzheimer’s disease (“Alzheimer’s” or “AD”). With two current and future product candidates, Alzamend aims to bring treatments or cures to market at a reasonable cost as quickly as possible. The Company’s current pipeline consists of two novel therapeutic drug candidates (collectively, the “Technology”): (i) a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001 or LiProSal, through two royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., as licensor, and (ii) a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing exclusive worldwide license from the same licensor. The Company is devoting substantially all its efforts towards research and development of its Technology and raising capital. The Company has not generated any product revenue to date. The Company has financed its operations to date primarily through debt financings and through the sale of its common stock, par value $0.0001 per share (the “Common Stock”). The Company expects to continue to incur net losses in the foreseeable future.

LIQUIDITY, GOING CONCERN AND MA

LIQUIDITY, GOING CONCERN AND MANAGEMENT'S PLANS	12 Months Ended
	Apr. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
LIQUIDITY, GOING CONCERN AND MANAGEMENT'S PLANS	2. LIQUIDITY, GOING CONCERN AND MANAGEMENT’S PLANS The accompanying financial statements have been prepared on the basis that the Company will continue as a going concern. As of April 30, 2021, the Company had cash of $1.9 million and an accumulated deficit of $16.8 million. The Company has incurred recurring losses for the year ended April 30, 2021 totaling $5.0 million. In the past, the Company has financed its operations principally through issuances of promissory notes and equity securities. In March of 2021, the Company entered into a securities purchase agreement with Digital Power Lending, a California limited liability company and wholly owned subsidiary of Ault Global Holdings, Inc. (“Ault Global”), or DPL, pursuant to which the Company agreed to sell an aggregate of 6,666,667 shares of Common Stock for an aggregate of $10 million, or $1.50 per share, which sales will be made in tranches. On March 9, 2021, DPL paid $4 million, less the $1.8 million in advances and the surrender for cancellation of the $50,000 convertible promissory note, each as described below, for an aggregate of 2,666,667 shares Common Stock. According to the securities purchase agreement, DPL will purchase an additional (i) 1,333,333 shares of Common Stock once the FDA shall have approved the Company’s IND for the Company’s phase 1a clinical trials for a purchase price of $2 million, and (ii) 2,666,667 shares of the Common Stock once the Company has completed these phase 1a clinical trials for a purchase price of $4 million. The Company further agreed to issue DPL warrants to purchase a number of shares of Common Stock equal to 50% of the shares of Common Stock purchased under the securities purchase agreement at an exercise price of $3.00 per share. Finally, the Company agreed that for a period of eighteen months following the date of the payment of the final tranche of $4 million, DPL will have the right to invest an additional $10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million as of the date of this Annual Report. The Company expects to continue to incur losses for the foreseeable future and needs to raise additional capital until it is able to generate revenues from operations sufficient to fund its development and commercial operations. However, based on the Company’s current business plan, management believes that the Company’s cash and cash equivalents at April 30, 2021, together with the funds received from the Company’s June 2021 initial public offering (see Note 13), are sufficient to meet the Company’s anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements included in this Annual Report. Impact of Coronavirus on the Company’s Operations In March 2020, the World Health Organization declared the outbreak of COVID-19 as a pandemic which continues to spread throughout the United States and the world. The Company is monitoring the outbreak of COVID-19 and the related business and travel restrictions and changes to behavior intended to reduce its spread, and its impact on our operations, financial position, cash flows, supply chains, and the industry in general, in addition to the impact on our employees. Due to the rapid development and fluidity of this situation, the magnitude and duration of the pandemic and its impact on our operations and liquidity is uncertain as of the date of this Annual Report. The continuing presence of COVID-19 has adversely impacted Alzamend’s business. The Company’s drug development and manufacturing activities for A001 were delayed by eight weeks due to a shutdown at our third-party manufacturing facility during the months of March to May 2020, which resulted in about a one-month overall delay in the clinical protocol development and IND development and submission as a result of a lack of labor and equipment. COVID-19 also delayed the nonclinical studies for AL002 by 12 weeks during the months of March to May 2020 due to shutdowns at third-party lab facilities where Alzamend was not granted access to perform research. The Company continues to assess and monitor its business operations and system supports and the impact COVID-19 may continue to have on its operations and financial condition, but there can be no assurance that this analysis will enable the Company to avoid part or all of any impact from the spread of COVID-19 or its consequences, including downturns in business sentiment generally or in Alzamend’s sector in particular. The Company’s operations are located in Orange County, CA and Tampa, FL, and certain members of the senior management work in Atlanta, GA and New York, NY. The Company has been following the recommendations of local health authorities to minimize exposure risk for its employees, including the temporary closures of our offices where certain employees work and having employees work remotely to the extent possible, has not negatively impacted their efficiency. Currently, the Company and its third-party facilities are working closely to pre-COVID-19 levels and expect normal operations for the balance of the calendar year.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Apr. 30, 2021
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	3. SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the “Commission”). Accounting Estimates The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s critical accounting policies that involve significant judgment and estimates include share-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of April 30, 2021 and April 30, 2020, the Company had no cash equivalents. Fair Value of Financial Instruments The Company’s financial instruments are accounts payable, notes payable and notes payable, related party. The recorded values of accounts payable approximate their fair values based on their short-term nature. The recorded values of notes payable and notes payable, related party are recorded at their carrying value, net of any unamortized debt discount, which approximates their fair value based on their short-term nature and as interest rates approximate market rates. U.S. GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock. The fair values of warrants are determined using the Black-Scholes valuation model, a “Level 3” fair value measurement, based on the estimated fair value of Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities, the expected life based on the remaining contractual term of the conversion option and warrants and the risk free interest rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrants’ contractual life. Income Taxes The Company determines its income taxes under the asset and liability method. Under the asset and liability approach, deferred income tax assets and liabilities are calculated and recorded based upon the future tax consequences of temporary differences by applying enacted statutory tax rates applicable to future periods for differences between the financial statements carrying amounts and the tax basis of existing assets and liabilities. Generally, deferred income taxes are classified as current or non-current in accordance with the classification of the related asset or liability. Those not related to an asset or a liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. Valuation allowances are provided for significant deferred income tax assets when it is more likely than not that some or all of the deferred tax assets will not be realized. As of April 30, 2021, the Company has fully reserved the net deferred income tax assets by taking a full valuation allowance against these assets. The Company recognizes tax liabilities by prescribing a minimum probability threshold that a tax position must meet before a financial statement benefit is recognized and also provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. The minimum threshold is defined as a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. To the extent that the final tax outcome of these matters is different than the amount recorded, such differences impact income tax expense in the period in which such determination is made. Interest and penalties, if any, related to accrued liabilities for potential tax assessments are included in income tax expense. U.S. GAAP also requires management to evaluate tax positions taken by the Company and recognize a liability if the Company has taken uncertain tax positions that more likely than not would not be sustained upon examination by applicable taxing authorities. Management of the Company has evaluated tax positions taken by the Company and has concluded that as of April 30, 2021, there are no uncertain tax positions taken, or expected to be taken, that would require recognition of a liability that would require disclosure in the financial statements. Research and Development Expenses Research and development costs are expensed as incurred. Research and development costs consist of scientific consulting fees and lab supplies, as well as fees paid to other entities that conduct certain research and development activities on behalf of the Company. The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license, product or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided that there is no alternative future use of the rights in other research and development projects. Stock-Based Compensation The Company maintains a stock-based compensation plan as a long-term incentive for employees, non-employee directors and consultants. The plan allows for the issuance of incentive stock options, non-qualified stock options, restricted stock units, and other forms of equity awards. The Company recognizes stock-based compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they occur. Our stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date. The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally require significant judgment. These assumptions include: · Fair Value of Common Stock. · Risk-Free Interest Rate. · Expected Volatility. · Expected Term. · Expected Dividend Yield. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the Company uses significantly different assumptions or estimates, our stock-based compensation could be materially different. Common Stock Valuations Prior to the Company’s initial public offering in June 2021, there was no public market for the Company’s Common Stock, and, as a result, the fair value of the shares of common stock underlying the Company’s share-based awards was estimated on each grant date by the board of directors. To determine the fair value of the Company’s Common Stock underlying option grants, the board of directors considered, among other things, input from management, and the board of directors’ assessment of additional objective and subjective factors that it believed were relevant, and factors that may have changed from the date of the most recent valuation through the date of the grant. These factors included, but were not limited to: · the Company’s results of operations and financial position, including its levels of available capital resources; · the Company’s stage of development and material risks related to its business; · progress of the Company’s research and development activities; · the Company’s business conditions and projections; · the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently completed mergers and acquisitions of peer companies; · the lack of marketability of our common stock as a private company; · the prices at which the Company sold shares of Common Stock to outside investors in arms-length transactions; · the likelihood of achieving a liquidity event for the Company’s security holders, such as an initial public offering or a sale of our company, given prevailing market conditions; · trends and developments in the Company’s industry; and · external market conditions affecting the life sciences and biotechnology industry sectors. Following the closing of the Company’s initial public offering, the board of directors will determine the fair market value of our common stock based on the closing price of the Company’s common stock as reported on the date of grant. Warrants The Company accounts for stock warrants as either equity instruments, derivative liabilities, or liabilities in accordance with Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity Derivatives and Hedging, Debt Issued with Warrants The Company considers guidance within ASC 470-20, Debt In circumstances in which debt is issued with equity-classified warrants, the proceeds from the issuance of convertible debt are allocated to the warrants and convertible debt based on their relative estimated fair value. The fair value of equity warrants is recorded as a discount to the convertible debt with a corresponding increase to additional paid-in capital. The debt discount is amortized as interest expense using the effective interest method. Embedded Derivatives. Beneficial Conversion Feature. The Company accounts for debt as liabilities measured at amortized cost and amortizes the resulting debt discount to interest expense using the effective interest method over the expected term of the Notes pursuant to ASC 835, Interest Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. Comprehensive Loss Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. There have been no items qualifying as other comprehensive loss, and, therefore, comprehensive loss for the periods reported was comprised solely of the Company’s net loss. Loss per Common Share The Company utilizes Financial Accounting Standards Board (“FASB”) ASC Topic No. 260, Earnings per Share Since the effects of outstanding options, warrants and convertible preferred stock are anti-dilutive in the periods presented, shares of Common Stock underlying these instruments have been excluded from the computation of loss per common share. The following sets forth the number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have been excluded from the computation of loss per common share: For the Year Ended April 30, 2021 2020 Series A convertible preferred stock 15,000,000 15,000,000 Stock options (1) 16,750,000 16,175,000 Warrants 8,102,868 6,652,035 Convertible notes 232,049 - 40,084,917 37,827,035 (1) The Company has excluded 7,500,000 stock options, with an exercise price of $0.0004, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-13. Reclassifications Certain prior period amounts have been reclassified for comparative purposes to conform to the current period financial statement presentation. These reclassifications had no effect on previously reported results of operations. Recent Accounting Standards From time to time, new accounting pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Company’s financial position or results of operations upon adoption. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement, In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40) The Company has considered all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on its financial statements.

NOTE RECEIVABLE, RELATED PARTY,

NOTE RECEIVABLE, RELATED PARTY, NET	12 Months Ended
	Apr. 30, 2021
Receivables [Abstract]
NOTE RECEIVABLE, RELATED PARTY, NET	4. NOTE RECEIVABLE, RELATED PARTY, NET On April 10, 2018, Avalanche International Corp., a related party (“Avalanche”), issued a promissory note (the “AVLP Note”) to the Company pursuant to which the Company agreed to provide Avalanche a loan of up to $995,500 for the period ending on April 30, 2019, subject to the terms and conditions stated in the AVLP Note. The AVLP Note accrues interest at 10% per annum and includes a 10% original issue discount. The balance outstanding on the AVLP Note as of April 30, 2020, was $100,915. During the month of August 2020, the principal and accrued interest on the AVLP Note was paid in full. In accordance with ASC No. 310, Receivables (“ASC 310”), the Company accounted for the AVLP Note at amortized cost, which represented the amount at which the promissory note was acquired, adjusted for accrued interest and accretion of original issue discount. Interest was accreted using the effective interest method. The Company recorded interest on an accrual basis and recognized it as earned in accordance with the contractual terms of the promissory note. The original issue discount of $90,500 was amortized as interest income through the maturity date. During the years ended April 30, 2021 and 2020, the Company recorded contractual interest income from the stated interest rate of $1,706 and $13,925, respectively. On April 30, 2019, the Company and Ault Life Sciences Fund, LLC (“ALSF”) entered into a securities purchase agreement for the purchase of 10,000,000 shares of the Company’s common stock for a total purchase price of $15,000,000, or $1.50 per share with 5,000,000 warrants with a 5-year life and an exercise price of $3.00 per share and vesting upon issuance. The total purchase price of $15,000,000 was in the form of a non-interest bearing note receivable with a 12-month term from ALSF, a related party. In November 2019, the term of the note receivable was extended to December 31, 2021, and in May 2021, the term of the note receivable was extended to December 31, 2023 (See Note 13). The note is secured by a pledge of the purchased shares. As the note receivable from ALSF is related to the issuance of common stock, it is recorded as an offset to additional paid-in capital. During the year ended April 30, 2021, proceeds from the note receivable for common stock, related party, were $99,905. The balance outstanding on the note receivable from ALSF as of April 30, 2021 was $14,883,295.

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	12 Months Ended
	Apr. 30, 2021
Prepaid Expense and Other Assets, Current [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	5. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets are as follows: April 30, 2021 April 30, 2020 Prepaid consulting fees $ 613,758 $ 1,513,602 Deferred offering costs 352,502 - Interest receivable - 77,153 Other prepaid expenses 850 15,850 Other receivables 16,210 16,210 Total prepaid expenses and other current assets $ 983,320 $ 1,622,815

INCOME TAXES

INCOME TAXES	12 Months Ended
	Apr. 30, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	6. INCOME TAXES The following is a geographical breakdown of the Company’s loss before the provision for income taxes: April 30, 2021 April 30, 2020 Pre-tax loss: Federal $ (5,046,567 ) $ (4,410,236 ) Foreign - - $ (5,046,567 ) $ (4,410,236 ) Significant components of the Company’s deferred tax assets are as follows: April 30, 2021 April 30, 2020 Deferred income tax asset: Net operating loss carryover $ 3,360,381 $ 2,333,201 Other temporary differences 994,264 511,093 Total deferred tax asset 4,354,645 2,844,294 Valuation allowance (4,354,645 ) (2,844,294 ) Deferred income tax asset, net of allowance $ - $ - A reconciliation of the federal statutory income tax rate to the Company’s effective income tax rate for the years ended April 30, is as follows: For the Year Ended April 30, 2021 2020 Tax benefit at U.S. Federal statutory tax rate 21.0 % 21.0 % Increase (decrease) in tax rate resulting from: Change in valuation allowance -15.9 % -20.9 % Other -5.1 % -0.1 % Effective tax rate 0.0 % 0.0 % In assessing the realization of deferred tax assets, management considers whether it is more likely than not the Company’s deferred tax assets will be realized. Management considers the scheduled reversal of deferred tax assets, projected future taxable income and tax planning strategies in making such assessment. Given historical generation of and expected future taxable losses, the Company determined it is not more likely than not to utilize its deferred tax assets. Therefore, a full valuation allowance is maintained, as of the years ended April 30, 2021 and April 30, 2020, of $4,354,645 and $2,844,294, respectively. At April 30, 2021, the Company maintains US Federal and state net operating loss (“NOL”) carryovers of approximately $11,571,832 and $11,430,017, respectively. Federal and state NOLs begin to expire in various years depending on relevant jurisdiction. In accordance with IRC §382, the future deductibility of the Company’s NOLs may be subject to an annual limitation in the event of a change in control as defined by applicable regulations. The Company has yet to complete a formal study to confirm NOLs are not limited in utilization per IRC §382 and may reduce applicable deferred tax assets upon completion of such a study, in future periods. The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. The Company has no uncertain tax positions as of April 30, 2021. The Company’s policy is to recognize interest and penalties related to income tax matters in the provision for income taxes. As of April 30, 2021, no interest or penalties have been recorded pertaining to uncertain tax positions. The Company is subject to taxation in the United States and various US state jurisdictions. All tax years remain open to examination by the Internal Revenue Service and relevant state authorities. On December 27, 2020, the Consolidated Appropriations Act, 2021 (CAA 2021) which included a number of provisions including, but not limited to the extension of numerous employment tax credits, the extension of the Section 179D deduction, enhanced business meals deductions, and the deductibility of expenses paid with Paycheck Protection Program (PPP) loan funds that are forgiven, was signed in to law. Accordingly, the effects of the CAA 2021 have been incorporated into the income tax provision for the year ended April 30, 2021. These provisions did not have a material impact on the income tax provision.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	12 Months Ended
	Apr. 30, 2021
Compensation Related Costs [Abstract]
STOCK-BASED COMPENSATION	6. STOCK-BASED COMPENSATION 2016 Stock Incentive Plan On April 30, 2016, the Company’s shareholders approved the Company’s 2016 Stock Incentive Plan (the “Plan”). The Plan provides for the issuance of a maximum of 12,500,000 shares of the Company’s Common Stock to be offered to the Company’s directors, officers, employees, and consultants. On March 1, 2019 the Company’s shareholders approved an additional 7,500,000 shares to be available for issuance under the Plan. Options granted under the Plan have an exercise price equal to or greater than the fair value of the underlying Common Stock at the date of grant and become exercisable based on a vesting schedule determined at the date of grant. The options expire between five and 10 years from the date of grant. Restricted stock awards granted under the Plan are subject to a vesting period determined at the date of grant. 2021 Stock Incentive Plan In February 2021, our Board of Directors adopted, and our stockholders approved, the Alzamend Neuro, Inc. 2021 Stock Incentive Plan (the “2021 Plan”). The 2021 Plan authorizes the grant to eligible individuals of (1) stock options (incentive and non-statutory), (2) restricted stock, (3) stock appreciation rights, or SARs, (4) restricted stock units, and (5) other stock-based compensation. Stock Subject to the 2021 Plan. All options that the Company grants are granted at the per share fair value on the grant date. Vesting of options differs based on the terms of each option. The Company has valued the options at their date of grant utilizing the Black Scholes option pricing model. As of the issuance of these financial statements, there was not an active public market for the Company’s shares. Accordingly, the fair value of the underlying options was determined based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options as calculated using the simplified method. The expected life of the options used was based on the contractual life of the option granted. Stock-based compensation is a non-cash expense because the Company settles these obligations by issuing shares of the Company’s Common Stock from its authorized shares instead of settling such obligations with cash payments. A summary of stock option activity for the period April 30, 2019 to April 30, 2021, is presented below: Outstanding Options Weighted Weighted Average Shares Average Remaining Aggregate Available for Number of Exercise Contractual Intrinsic Grant Options Price Life (years) Value Balance at April 30, 2019 4,290,000 15,710,000 $ 0.5228 7.51 $ 15,352,000 Options granted (3,750,000 ) 3,750,000 $ 1.4267 Options cancelled/forfeited 35,000 (35,000 ) $ 1.0000 Balance at April 30, 2020 575,000 19,425,000 $ 0.6964 6.89 $ 15,609,500 Increase to plan shares 10,000,000 Options granted (125,000 ) 125,000 $ 1.5000 Balance at April 30, 2021 10,450,000 19,550,000 $ 0.7195 5.92 $ 35,159,500 Options vested and expected to vest at 17,550,000 $ 0.6675 6.47 $ 32,159,500 Options exercisable at April 30, 2021 12,998,896 $ 0.4763 5.98 $ 26,306,032 The aggregate intrinsic value in the table above represents the total pretax intrinsic value (i.e., the difference between the estimated fair value price on the respective date and the exercise price, times the number of shares) that would have been received by the option holders had all option holders exercised their options. There have not been any options exercised during the years ended April 30, 2021 and 2020. Stock options granted to employees and consultants The estimated fair value of stock options granted to employees and consultants during the year ended April 30, 2021 and 2020, were calculated using the Black-Scholes option-pricing model using the following assumptions: For the Year Ended April 30, 2021 2020 Expected term (in years) 3.50 - 6.25 2.50 - 6.25 Volatility 85.53% -100.09% 65.80% -72.35% Risk-free interest rate 0.31% -0.51% 1.52% -2.36% Dividend yield 0.0% 0.0% Expected Term: Expected Volatility: Risk-Free Interest Rate: Expected Dividend: Stock-based compensation to employees and consultants from stock option grants for the year ended April 30, 2021 and 2020 was $1,479,231 and $1,293,915, respectively. Performance-contingent stock options granted to employee In November 2018, the Board of Directors granted 2,000,000 performance-contingent options under the Plan to the Chief Executive Officer. These options have an exercise price of $1.00 per share. These options have two separate performance triggers for vesting based upon our therapies achieving certain FDA approval milestones within a specified timeframe. By definition, the performance condition in these options can only be achieved after the performance condition of FDA approval has been achieved. As such, the requisite service period is based on the estimated period over which the market condition can be achieved. When a performance goal is deemed to be probable of achievement, time-based vesting and recognition of stock-based compensation expense commences. In the event any the milestones are not achieved by the specified timelines, such vesting award will terminate and no longer be exercisable with respect to that portion of the shares. The maximum potential expense associated with the performance-contingent awards is $1.2 million of general and administrative expense if all of the performance conditions are achieved as stated in the option agreement. Due to the significant risks and uncertainties associated with FDA approvals, through April 30, 2021, the Company believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for these awards. On November 26, 2019, the Board of Directors granted 4,250,000 performance- and market-contingent awards to certain key employees and a director. These grants were made outside of the Plan. These awards have an exercise price of $1.50 per share. These awards have multiple separate market triggers for vesting based upon either (i) the successful achievement of stepped target closing prices on a national securities exchange for 90 consecutive trading days later than 180 days after the Company’s initial public offering for its common stock, or (ii) stepped target prices for a change in control transaction. The target prices range from $15 per share to $40 per share. In the event any the stock price milestones are not achieved within three years, the unvested portion of the performance options will be reduced by 25%. Due to the significant risks and uncertainties associated with achieving the market-contingent awards, through April 30, 2021, the Company believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for these awards. Stock issued for uplisting agreement compensation Pursuant to the Uplisting Agreement, defined below, the Company issued to the Advisor 500,000 shares of Common Stock, valued at the $1.3668 estimated grant date fair value of the stock on the July 10, 2019 date of issuance. The stock compensation expense is being recognized over the two-year term of the agreement. During the year ended April 30, 2021 and 2020, the Company recognized stock compensation expense of $378,704 and $303,724, respectively, related to the Uplisting Agreement and as of April 30, 2021 the stock compensation expense related to the Uplisting Agreement has been fully amortized. Stock issued for placement agent compensation Upon the initial closing of the 2019 PPM, defined below, the Company issued to the Placement Agent 500,000 shares of Common Stock valued at the $1.3668 estimated grant date fair value of the stock on the August 30, 2019 date of issuance. The consideration was considered to be a cost of the equity offering, and accordingly, was netted against offering proceeds within additional paid in capital. Stock-based compensation expense The Company’s results of operations include expenses relating to stock-based compensation as follows: For the Year Ended April 30, 2021 2020 Research and development $ 87,252 $ 309,499 General and administrative 2,286,794 1,945,741 Total $ 2,374,046 $ 2,255,240 As of April 30, 2021, total unamortized stock-based compensation expense related to unvested employee and non-employee awards that are expected to vest was $3.7 million. The weighted-average period over which such stock-based compensation expense will be recognized is approximately 1.9 years. As of April 30, 2020, total unamortized stock-based compensation expense related to unvested employee and non-employee awards that are expected to vest was $6.0 million. The weighted-average period over which such stock-based compensation expense will be recognized is approximately 2.6 years.

WARRANTS

WARRANTS	12 Months Ended
	Apr. 30, 2021
Warrants and Rights Note Disclosure [Abstract]
WARRANTS	7. WARRANTS During the year ended April 30, 2021, the Company issued warrants to purchase an aggregate of 123,000 shares of Common Stock at an exercise price of $3.00 per share. (i) On August 11, 2020, the Company issued a warrant to purchase an aggregate of 91,667 shares of Common Stock at an exercise price equal to $3.00 per share of Common Stock in connection with the issuance of a convertible promissory note in the principal amount of $275,000 (see Note 9). Based on the terms of the Company’s warrant agreement, the Company accounted for the warrant as an equity instrument as the warrant is indexed to the Company’s Common Stock, require settlement in shares and would be classified as equity under ASC 815. (ii) On August 31, 2020, the Company issued a warrant to purchase an aggregate of 16,667 shares of Common Stock at an exercise price equal to $3.00 per share of Common Stock in connection with the issuance of a convertible promissory note, related party in the principal amount of $50,000 (see Note 11). Based on the terms of the Company’s warrant agreement, the Company accounted for the warrant as equity instrument as the warrant is indexed to the Company’s Common Stock, require settlement in shares and would be classified as equity under ASC 815. (iii) In December 2020, the Company issued a warrant to purchase an aggregate of 14,666 shares of Common Stock at an exercise price equal to $3.00 per share of Common Stock in connection with the issuance of a convertible promissory note in the principal amount of $44,000 (see Note 9). Based on the terms of the Company’s warrant agreement, the Company accounted for the warrant as equity instruments as the warrant is indexed to the Company’s Common Stock, require settlement in shares and would be classified as equity under ASC 815. In conjunction with a private offering of securities between June 25, 2019 and October 31, 2019, the Company issued 878,358 warrants with an exercise price of $3.00 per share. In addition, the Company issued to the placement agent of the private offering 175,672 warrants to purchase a number of shares of Common Stock (the “Placement Agent Warrants”), a figure equal to ten percent (10%) of the number of shares of Common Stock sold in the private offering. The Placement Agent Warrants are exercisable for a period of five years after their date of issuance, have an exercise price of $1.75 per share and contain provisions pertaining to cashless exercise, standard anti-dilution protection and piggyback registration rights. The grant date fair value of the Placement Agent Warrants was $95,467 and was recorded within additional paid-in capital. The following table summarizes information about Common Stock warrants outstanding at April 30, 2021: Outstanding Exercisable Weighted Average Weighted Weighted Remaining Average Average Exercise Number Contractual Exercise Number Exercise Price Outstanding Life (years) Price Exercisable Price $1.00 500,000 3.1 $ 1.00 500,000 $ 1.00 $1.75 175,672 3.8 $ 1.75 175,672 $ 1.75 $3.00 7,427,196 3.5 $ 3.00 7,427,196 $ 3.00 $1.00 - $3.00 8,102,868 3.7 $ 2.85 8,102,868 $ 2.85 The estimated fair value of warrants granted during the year ended April 30, 2021 and 2020, were calculated using the Black-Scholes option-pricing model using the following assumptions: For the Year Ended April 30, 2021 2020 Common stock price $1.50 $1.50 Expected term (in years) 5.00 2.50 Volatility 103.70% 66% Risk-free interest rate 0.27% - 0.28% 1.52% Dividend yield 0.00% 0.00% Expected Term: Expected Volatility: Risk-Free Interest Rate: Expected Dividend:

OTHER RELATED PARTY TRANSACTION

OTHER RELATED PARTY TRANSACTIONS	12 Months Ended
	Apr. 30, 2021
Related Party Transactions [Abstract]
OTHER RELATED PARTY TRANSACTIONS	8. OTHER RELATED PARTY TRANSACTIONS On June 28, 2017, MCKEA and Spartan Capital Securities, LLC (“Spartan”) entered into a five-year consulting agreement (the “MCKEA Consulting Agreement”). Pursuant to the MCKEA Consulting Agreement, upon the receipt by us of no less than $2,500,000 in gross proceeds from a Private Placement Memorandum dated August 17, 2017, MCKEA transferred to Spartan 5,000,000 shares of Alzamend Common Stock. During the term of the MCKEA Consulting Agreement, Spartan would provide consulting services to MCKEA related to general corporate and other matters related to MCKEA’s investment in us such as advice on mergers and acquisition transactions, finance strategies, identification of potential management candidates and other strategic introductions. The 5,000,000 shares of Common Stock were transferred by MCKEA to Spartan on January 31, 2018. In August 2020, the Company entered into a securities purchase agreement with Ault Global to sell a convertible promissory note in the principal amount of $50,000 and issue a five-year warrant to purchase 16,667 shares of our Common Stock. The convertible promissory note bears interest at 8% per annum, which principal and all accrued and unpaid interest are due six months after the date of issuance. The principal and interest earned on the convertible promissory note may be converted into shares of Common Stock at $1.50 per share. The exercise price of the warrant is $3.00 per share. The convertible note was cancelled for shares of Common Stock received pursuant to the March 2021 securities purchase agreement with Digital Power Lending (“DPL”), a California limited liability company and wholly owned subsidiary of Ault Global, described below. In December 2020 and February 2021, Ault Global provided $800,000 and $1,000,000, respectively, in short-term advances to the Company for working capital needs. The $1.8 million obligation related to the short-term advances was satisfied with shares of Common Stock received pursuant to the March 2021 securities purchase agreement with DPL described below In March 2021, the Company entered into a securities purchase agreement with DPL pursuant to which the Company agreed to sell an aggregate of 6,666,667 shares of Common Stock for an aggregate of $10 million, or $1.50 per share, which sales will be made in tranches. On March 9, 2021, DPL paid $4 million, less the $1.8 million in advances and the surrender for cancellation of a $50,000 convertible promissory note held by Ault Global, each as described below, for an aggregate of 2,666,667 shares of Common Stock. Under the terms of the securities purchase agreement, DPL will purchase an additional (i) 1,333,333 shares of Common Stock if and upon approval by the FDA of our IND for our Phase Ia clinical trials for a purchase price of $2 million, and (ii) 2,666,667 shares of our Common Stock upon the completion of these Phase Ia clinical trials for a purchase price of $4 million. As of the date this Annual Report, the milestones related to additional funding have not been acheived. The Company further agreed to issue to DPL warrants to purchase a number of shares of Common Stock equal to 50% of the shares of Common Stock purchased under the securities purchase agreement at an exercise price of $3.00 per share. Finally, the Company agreed that for a period of 18 months following the date of the payment of the final tranche of $4 million, DPL will have the right to invest an additional $10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million as of the date of this Annual Report.

CONVERTIBLE NOTES

CONVERTIBLE NOTES	12 Months Ended
	Apr. 30, 2021
Long-term Debt, Unclassified [Abstract]
CONVERTIBLE NOTES	9. CONVERTIBLE NOTES In August 2020, the Company entered into a securities purchase agreement with an institutional investor to sell a Convertible Promissory Note in the aggregate principal amount of $275,000 for a purchase price of $250,000 and issue a 5-year warrant to purchase 91,667 of shares of Common Stock. The Convertible Promissory Note bears interest at 8% per annum, which principal and all accrued and unpaid interest are due six months from the date of issuance. The principal and interest earned on the Convertible Promissory Note may be converted into shares of Common Stock at $1.50 per share any time on or after the maturity date. The exercise price of the warrant is $3.00 per share. In December 2020, the Company entered into a securities purchase agreement with the same institutional investor to sell a Convertible Promissory Note in the aggregate principal amount of $44,000 for a purchase price of $40,000 and issue a 5-year warrant to purchase 14,667 of shares Common Stock. The Convertible Promissory Note bears interest at 8% per annum, which principal and all accrued and unpaid interest are due six months from the date of issuance. The principal and interest earned on the Convertible Promissory Note may be converted into shares of Common Stock at $1.50 per share. The exercise price of the warrant is $3.00 per share. In February 2021, the Company entered into a securities purchase agreement with the same institutional investor to sell a Convertible Promissory Note in the aggregate principal amount of $348,073 for a purchase price of $331,498. The purchase price of the February 2021 Convertible Promissory Note satisfies the principal and accrued interest of the August 2020 and December 2020 Convertible Promissory Notes with the institutional investor. Since the terms of the February 2021 Convertible Promissory Note were not substantially different from the August 2020 and December 2020 Convertible Promissory Notes, no gain or loss was recognized as a result of this debt issuance. The Convertible Promissory Note bears interest at 10% per annum, which principal and all accrued and unpaid interest are due on December 31, 2021. The principal and interest earned on the Convertible Promissory Note may be converted into shares of Common Stock at $1.50 per share. The fair value of equity warrants was recorded as a discount to the convertible promissory note with a corresponding increase to additional paid-in capital. The Company computed the estimated fair value of the warrants using the Black-Scholes option pricing model and, as a result of this calculation, recorded debt discount in the amount of $91,241 based on the estimated fair value of the warrants. The risk-free rate of 0.27% was derived from the U.S. Treasury yield curve, matching the term of the warrant, in effect at the measurement date. The volatility factor of 103.7% was determined based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities. In aggregate, the Company recorded debt discount in the amount of $136,816 based on the fair values of the warrants and original issue discount of $45,575. As of April 30, 2021, the convertible note is presented net of unamortized debt discount of $12,770.

NOTES PAYABLE

NOTES PAYABLE	12 Months Ended
	Apr. 30, 2021
Notes Payable [Abstract]
NOTES PAYABLE	10. NOTE PAYABLE In May 2020, the Company received loan proceeds in the amount of $62,110 under the Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest are forgivable after the earlier of (i) 24 weeks after the loan disbursement date and (ii) December 31, 2020 as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. In December 2020, the Company met the conditions and received forgiveness of the $62,110 principal amount of the loan and $308 of accrued interest payable.

CONVERTIBLE NOTE - RELATED PART

CONVERTIBLE NOTE - RELATED PARTY	12 Months Ended
	Apr. 30, 2021
Long-term Debt, Unclassified [Abstract]
CONVERTIBLE NOTE - RELATED PARTY	11. CONVERTIBLE NOTE – RELATED PARTY In August 2020, the Company entered into a securities purchase agreement with Ault Global to sell a convertible promissory note in the aggregate principal amount of $50,000 and issue a 5-year warrant to purchase 16,667 shares of Common Stock. The convertible promissory note bears interest at 8% per annum, which principal and all accrued and unpaid interest are due six months from the date of issuance. The principal and interest earned on the convertible promissory note may be converted into shares of the Company’s Common Stock at $1.50 per share any time on or after the maturity date. The exercise price of the warrant is $3.00 per share. The fair value of the equity warrant was recorded as a discount to the convertible promissory note with a corresponding increase to additional paid-in capital. The Company computed the estimated fair value of the warrants using the Black-Scholes option pricing model and, as a result of this calculation, recorded debt discount in the amount of $14,300 based on the estimated fair value of the warrants. The risk-free rate of 0.28% was derived from the U.S. Treasury yield curve, matching the term of the warrant, in effect at the measurement date. The volatility factor of 103.7% was determined based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities. The convertible promissory note was cancelled in March 2021 pursuant to a securities purchase agreement with DPL (see Note 8).

EQUITY TRANSACTIONS

EQUITY TRANSACTIONS	12 Months Ended
	Apr. 30, 2021
Equity [Abstract]
EQUITY TRANSACTIONS	12. EQUITY TRANSACTIONS The Company is authorized to issue 10,000,000 shares of Preferred Stock $0.0001 par value. The Board of Directors has designated 1,360,000 shares as Series A Convertible Preferred Stock (the “Series A Preferred Shares”), The rights, preferences, privileges and restrictions on the remaining authorized 8,640,000 shares of Preferred Stock have not been determined. The Company’s Board of Directors is authorized to create a new series of preferred shares and determine the number of shares, as well as the rights, preferences, privileges and restrictions granted to or imposed upon any series of preferred shares. As of April 30, 2021, there were 750,000 shares of Series A Preferred Shares and no other shares of Preferred Stock issued or outstanding. Series A Preferred Stock The Series A Preferred Shares convey no dividend rights except as may be declared by the Board in its sole and absolute discretion, out of funds legally available for that purpose. Holders of Series A Preferred Shares are entitled to fifty (50) non-cumulative votes per share on all matters presented to our stockholders for action. In addition, the affirmative vote of the holders of a majority of the Series A Preferred then outstanding, voting as a separate class, is required for the Company to: · amend, alter or repeal any of the preferences or rights of the Series A Preferred Shares; · authorize any reclassification of the Series A Preferred Shares; · increase the authorized number of Series A Preferred Shares; or · create any class or series of shares ranking prior to the Series A Preferred Shares as to dividends or liquidation. The Series A Preferred Shares are not entitled to preemptive rights. In the event of any dissolution, liquidation or winding up of the Company, whether voluntary or involuntary, the Holders of Series A Preferred Shares shall be entitled to participate in any distribution out of the assets of the Company on an equal basis per share with the holders of the Common Stock. Holders of Series A Preferred Shares have the right to convert their shares into shares of Common Stock at any time at a conversion rate equal to twenty (20) shares of Common Stock for every one (1) Series A Preferred Share. The conversion rate is not subject to anti-dilution adjustments. Common Stock On May 27, 2016, the Company’s Board of Directors approved a Certificate of Amendment to the Company’s Certificate of Incorporation increasing its authorized shares of Common Stock from 150,000,000 to 300,000,000. On April 30, 2019, the Company and ALSF entered into a SPA for the purchase of 10,000,000 shares of Common Stock for a total purchase price of $15,000,000, or $1.50 per share with 5,000,000 warrants with a 5-year life and an exercise price of $3.00 per share and vesting upon issuance. The total purchase price of $15,000,000 was in the form of a non-interest bearing note receivable with a 12-month term from ALSF, a related party. The note is secured by a pledge of the purchased shares. Pursuant to the SPA, ALSF is entitled to full ratchet anti-dilution protection, most-favored nation status, denying the Company the right to enter into a variable rate transaction absent its consent, a right to participate in any future financing the Company may consummate and to have all the shares of Common Stock to which it is entitled under the SPA registered under the Securities Act within 180 days of the final closing of an initial public offering. In March 2021, the Company entered into a securities purchase agreement with Digital Power Lending (“DPL”), a California limited liability company and wholly owned subsidiary of Ault Global, pursuant to which the Company agreed to sell an aggregate of 6,666,667 shares of Common Stock for an aggregate of $10 million, or $1.50 per share, which sales will be made in tranches. On March 9, 2021, DPL paid $4 million, less the $1.8 million in advances and the surrender for cancellation of a $50,000 convertible promissory note held by Ault Global, each as described below, for an aggregate of 2,666,667 shares of Common Stock. Under the terms of the securities purchase agreement, DPL will purchase an additional (i) 1,333,333 shares of Common Stock if and upon approval by the FDA of our IND for our Phase Ia clinical trials for a purchase price of $2 million, and (ii) 2,666,667 shares of our Common Stock upon the completion of these Phase Ia clinical trials for a purchase price of $4 million. The Company further agreed to issue to DPL warrants to purchase a number of shares of Common Stock equal to 50% of the shares of Common Stock purchased under the securities purchase agreement at an exercise price of $3.00 per share. Finally, the Company agreed that for a period of 18 months following the date of the payment of the final tranche of $4 million, DPL will have the right to invest an additional $10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million as of the date of this Annual Report. 2019 Placement Agreement Between June 25, 2019 and October 31, 2019, the Company entered into subscription agreements for the purchase of 1,756,726 units at $1.50 for each unit purchased pursuant to its 2019 private offering (the “2019 Offering”). Each unit consists of one (1) share of Common Stock and one (1) warrant to purchase one half (0.5) share of Common Stock. In aggregate, the 1,756,726 units represents 1,756,726 shares of Common Stock and 878,363 warrants with an exercise price of $3.00 per share for an aggregate purchase price of $2,635,089, or $1.50 per share. The 2019 Offering was conducted pursuant to the terms of a Confidential Private Placement Memorandum dated June 12, 2019 (the “2019 PPM”). As of April 30, 2019, in conjunction with the 2019 PPM, the Company incurred $395,263 in placement fees resulting in net proceeds to the Company of $2,239,826. Upon the initial closing of the 2019 PPM the Company paid to the Placement Agent a non-refundable fee of Twenty-Five Thousand Dollars ($25,000) and issued to the Placement Agent 500,000 shares of Common Stock. Further, the Company has issued to the Placement Agent warrants to purchase a number of shares of Common Stock (the “Placement Agent Warrants”) equal to ten percent (10%) of the number of shares of Common Stock sold in the 2019 PPM. The Placement Agent Warrants are exercisable for a period of five (5) years after their date of issuance, have an exercise price of $1.75 per share and contain provisions pertaining to cashless exercise, standard anti-dilution protection and piggyback registration rights. The Company applied the net proceeds from the 2019 Offering primarily: (i) for licensing and other fees to the University and the Byrd Institute; (ii) to pay certain fees to the FDA; (iii) to pay for third-party research; (iv) to pay certain marketing-related fees, and (v) for working capital. Uplisting Agreement Pursuant to the Uplisting Agreement effective as of June 10, 2019 the Company engaged the Placement Agent as an advisor (in such capacity, the “Advisor”) to provide advisory services (the “Services”) to the Company in connection with a public offering (an “IPO”). The Services rendered consisted principally of advising the Company on how to properly develop and implement strategies that would enhance its ability to successfully complete an IPO and in connection therewith obtain a listing on a national securities exchange. According to the Uplisting Agreement, the Company issued to the Advisor Five Hundred Thousand (500,000) shares of Common Stock and made a cash payment to the Advisor in the amount of $475,000.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Apr. 30, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	13. SUBSEQUENT EVENTS In accordance with FASB ASC 855-10, the Company has analyzed its operations subsequent to April 30, 2021 and has determined that it does not have any material subsequent events to disclose in these financial statements except for the following: In May 2021, the Board of Directors of our company and Mr. Ault, our Founder and Chairman Emeritus, agreed to certain arrangements with regard to Board composition and other matters. Contemporaneously with the effectiveness of the initial public offering, and in consideration for (i) the conversion of 750 shares of our series A convertible preferred stock beneficially owned by Mr. Ault through Ault Life Sciences, Inc. into 15,000,000 shares of Common Stock, (ii) the extension of the maturity date of the note in the original principal amount of $15,000,000 issued to the Company by Ault Life Sciences Fund, LLC, an entity controlled by Mr. Ault, to December 31, 2023, and (iii) the retirement by Mr. Ault as a director and executive officer of the Company, the Board agreed that William B. Horne will become Chairman of the Board and remain in that position for so long as Mr. Ault beneficially owns no less than 5% of the outstanding shares of Common Stock (for which Mr. Horne will be paid $50,000 per year for his services), and Mr. Nisser will remain a member of our Board of Directors for so long as Mr. Ault beneficially owns no less than 5% of the outstanding shares of Common Stock (for no additional remuneration). Additionally, Mr. Ault will hold the position of Founder and Chairman Emeritus and, as such, have the right to nominate an observer to the Board of Directors for a period of five years after the closing date of the initial public offering. Following the closing of the initial public offering, the Company entered into a five-year consulting agreement with Mr. Ault under which he will provide strategic advisory and consulting services to the Company in consideration for annual fees of $50,000. On June 17, 2021 the Company announced the closing of the Company’s initial public offering of 2,500,000 shares of its common stock and full exercise of the underwriter’s over-allotment option to purchase 375,000 additional shares of common stock at a price to the public of $5.00 per share. The gross proceeds from the offering to the Company, before deducting the underwriting discounts and estimated offering expenses, were approximately $14.4 million. The Company’s common stock is listed on The Nasdaq Capital Market under the ticker symbol “ALZN”.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Apr. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the “Commission”).
Accounting Estimates	Accounting Estimates The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s critical accounting policies that involve significant judgment and estimates include share-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of April 30, 2021 and April 30, 2020, the Company had no cash equivalents.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments are accounts payable, notes payable and notes payable, related party. The recorded values of accounts payable approximate their fair values based on their short-term nature. The recorded values of notes payable and notes payable, related party are recorded at their carrying value, net of any unamortized debt discount, which approximates their fair value based on their short-term nature and as interest rates approximate market rates. U.S. GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock. The fair values of warrants are determined using the Black-Scholes valuation model, a “Level 3” fair value measurement, based on the estimated fair value of Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities, the expected life based on the remaining contractual term of the conversion option and warrants and the risk free interest rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrants’ contractual life.
Income Taxes	Income Taxes The Company determines its income taxes under the asset and liability method. Under the asset and liability approach, deferred income tax assets and liabilities are calculated and recorded based upon the future tax consequences of temporary differences by applying enacted statutory tax rates applicable to future periods for differences between the financial statements carrying amounts and the tax basis of existing assets and liabilities. Generally, deferred income taxes are classified as current or non-current in accordance with the classification of the related asset or liability. Those not related to an asset or a liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. Valuation allowances are provided for significant deferred income tax assets when it is more likely than not that some or all of the deferred tax assets will not be realized. As of April 30, 2021, the Company has fully reserved the net deferred income tax assets by taking a full valuation allowance against these assets. The Company recognizes tax liabilities by prescribing a minimum probability threshold that a tax position must meet before a financial statement benefit is recognized and also provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. The minimum threshold is defined as a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. To the extent that the final tax outcome of these matters is different than the amount recorded, such differences impact income tax expense in the period in which such determination is made. Interest and penalties, if any, related to accrued liabilities for potential tax assessments are included in income tax expense. U.S. GAAP also requires management to evaluate tax positions taken by the Company and recognize a liability if the Company has taken uncertain tax positions that more likely than not would not be sustained upon examination by applicable taxing authorities. Management of the Company has evaluated tax positions taken by the Company and has concluded that as of April 30, 2021, there are no uncertain tax positions taken, or expected to be taken, that would require recognition of a liability that would require disclosure in the financial statements.
Research and Development Expenses	Research and Development Expenses Research and development costs are expensed as incurred. Research and development costs consist of scientific consulting fees and lab supplies, as well as fees paid to other entities that conduct certain research and development activities on behalf of the Company. The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license, product or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided that there is no alternative future use of the rights in other research and development projects.
Stock-Based Compensation	Stock-Based Compensation The Company maintains a stock-based compensation plan as a long-term incentive for employees, non-employee directors and consultants. The plan allows for the issuance of incentive stock options, non-qualified stock options, restricted stock units, and other forms of equity awards. The Company recognizes stock-based compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they occur. Our stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date. The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally require significant judgment. These assumptions include: · Fair Value of Common Stock. · Risk-Free Interest Rate. · Expected Volatility. · Expected Term. · Expected Dividend Yield. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the Company uses significantly different assumptions or estimates, our stock-based compensation could be materially different.
Common Stock Valuations	Common Stock Valuations Prior to the Company’s initial public offering in June 2021, there was no public market for the Company’s Common Stock, and, as a result, the fair value of the shares of common stock underlying the Company’s share-based awards was estimated on each grant date by the board of directors. To determine the fair value of the Company’s Common Stock underlying option grants, the board of directors considered, among other things, input from management, and the board of directors’ assessment of additional objective and subjective factors that it believed were relevant, and factors that may have changed from the date of the most recent valuation through the date of the grant. These factors included, but were not limited to: · the Company’s results of operations and financial position, including its levels of available capital resources; · the Company’s stage of development and material risks related to its business; · progress of the Company’s research and development activities; · the Company’s business conditions and projections; · the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently completed mergers and acquisitions of peer companies; · the lack of marketability of our common stock as a private company; · the prices at which the Company sold shares of Common Stock to outside investors in arms-length transactions; · the likelihood of achieving a liquidity event for the Company’s security holders, such as an initial public offering or a sale of our company, given prevailing market conditions; · trends and developments in the Company’s industry; and · external market conditions affecting the life sciences and biotechnology industry sectors. Following the closing of the Company’s initial public offering, the board of directors will determine the fair market value of our common stock based on the closing price of the Company’s common stock as reported on the date of grant.
Warrants	Warrants The Company accounts for stock warrants as either equity instruments, derivative liabilities, or liabilities in accordance with Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity Derivatives and Hedging,
Debt Issued with Warrants	Debt Issued with Warrants The Company considers guidance within ASC 470-20, Debt In circumstances in which debt is issued with equity-classified warrants, the proceeds from the issuance of convertible debt are allocated to the warrants and convertible debt based on their relative estimated fair value. The fair value of equity warrants is recorded as a discount to the convertible debt with a corresponding increase to additional paid-in capital. The debt discount is amortized as interest expense using the effective interest method. Embedded Derivatives. Beneficial Conversion Feature. The Company accounts for debt as liabilities measured at amortized cost and amortizes the resulting debt discount to interest expense using the effective interest method over the expected term of the Notes pursuant to ASC 835, Interest
Emerging Growth Company Status	Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.
Comprehensive Loss	Comprehensive Loss Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. There have been no items qualifying as other comprehensive loss, and, therefore, comprehensive loss for the periods reported was comprised solely of the Company’s net loss.
Loss per Common Share	Loss per Common Share The Company utilizes Financial Accounting Standards Board (“FASB”) ASC Topic No. 260, Earnings per Share Since the effects of outstanding options, warrants and convertible preferred stock are anti-dilutive in the periods presented, shares of Common Stock underlying these instruments have been excluded from the computation of loss per common share. The following sets forth the number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have been excluded from the computation of loss per common share: For the Year Ended April 30, 2021 2020 Series A convertible preferred stock 15,000,000 15,000,000 Stock options (1) 16,750,000 16,175,000 Warrants 8,102,868 6,652,035 Convertible notes 232,049 - 40,084,917 37,827,035 (1) The Company has excluded 7,500,000 stock options, with an exercise price of $0.0004, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-13.
Reclassification	Reclassifications Certain prior period amounts have been reclassified for comparative purposes to conform to the current period financial statement presentation. These reclassifications had no effect on previously reported results of operations.
Recent Accounting Standards	Recent Accounting Standards From time to time, new accounting pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Company’s financial position or results of operations upon adoption. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement, In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40) The Company has considered all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on its financial statements.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Apr. 30, 2021
Accounting Policies [Abstract]
Schedule of anti-dilutive loss per common share	The following sets forth the number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have been excluded from the computation of loss per common share: For the Year Ended April 30, 2021 2020 Series A convertible preferred stock 15,000,000 15,000,000 Stock options (1) 16,750,000 16,175,000 Warrants 8,102,868 6,652,035 Convertible notes 232,049 - 40,084,917 37,827,035 (1) The Company has excluded 7,500,000 stock options, with an exercise price of $0.0004, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-13.

PREPAID EXPENSES AND OTHER CU_2

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	12 Months Ended
	Apr. 30, 2021
Prepaid Expense and Other Assets, Current [Abstract]
Schedule of prepaid expenses and other current assets	Prepaid expenses and other current assets are as follows: April 30, 2021 April 30, 2020 Prepaid consulting fees $ 613,758 $ 1,513,602 Deferred offering costs 302,502 - Interest receivable - 77,153 Other prepaid expenses 850 15,850 Other receivables 16,210 16,210 Total prepaid expenses and other current assets $ 933,320 $ 1,622,815

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Apr. 30, 2021
Income Tax Disclosure [Abstract]
Schedule of geographical breakdown of income before	The following is a geographical breakdown of the Company’s loss before the provision for income taxes: April 30, 2021 April 30, 2020 Pre-tax loss: Federal $ (5,046,567 ) $ (4,410,236 ) Foreign - - $ (5,046,567 ) $ (4,410,236 )
Schedule of deferred tax assets	Significant components of the Company’s deferred tax assets are as follows: April 30, 2021 April 30, 2020 Deferred income tax asset: Net operating loss carryover $ 3,360,381 $ 2,333,201 Other temporary differences 994,264 511,093 Total deferred tax asset 4,354,645 2,844,294 Valuation allowance (4,354,645 ) (2,844,294 ) Deferred income tax asset, net of allowance $ - $ -
Schedule of reconciliation of federal statutory income tax rate	A reconciliation of the federal statutory income tax rate to the Company’s effective income tax rate for the years ended April 30, is as follows: For the Year Ended April 30, 2021 2020 Tax benefit at U.S. Federal statutory tax rate 21.0 % 21.0 % Increase (decrease) in tax rate resulting from: Change in valuation allowance -15.9 % -20.9 % Other -5.1 % -0.1 % Effective tax rate 0.0 % 0.0 %

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	12 Months Ended
	Apr. 30, 2021
Compensation Related Costs [Abstract]
Schedule of stock option activity	A summary of stock option activity for the period April 30, 2019 to April 30, 2021, is presented below: Outstanding Options Weighted Weighted Average Shares Average Remaining Aggregate Available for Number of Exercise Contractual Intrinsic Grant Options Price Life (years) Value Balance at April 30, 2019 4,290,000 15,710,000 $ 0.5228 7.51 $ 15,352,000 Options granted (3,750,000 ) 3,750,000 $ 1.4267 Options cancelled/forfeited 35,000 (35,000 ) $ 1.0000 Balance at April 30, 2020 575,000 19,425,000 $ 0.6964 6.89 $ 15,609,500 Increase to plan shares 10,000,000 Options granted (125,000 ) 125,000 $ 1.5000 Balance at April 30, 2021 10,450,000 19,550,000 $ 0.7195 5.92 $ 35,159,500 Options vested and expected to vest at 17,550,000 $ 0.6675 6.47 $ 32,159,500 Options exercisable at April 30, 2021 12,998,896 $ 0.4763 5.98 $ 26,306,032
Schedule of stock options granted to employees and consultants	The estimated fair value of stock options granted to employees and consultants during the year ended April 30, 2021 and 2020, were calculated using the Black-Scholes option-pricing model using the following assumptions: For the Year Ended April 30, 2021 2020 Expected term (in years) 3.50 - 6.25 2.50 - 6.25 Volatility 85.53% -100.09% 65.80% -72.35% Risk-free interest rate 0.31% -0.51% 1.52% -2.36% Dividend yield 0.0% 0.0%
Schedule of stock-based compensation expense	The Company’s results of operations include expenses relating to stock-based compensation as follows: For the Year Ended April 30, 2021 2020 Research and development $ 87,252 $ 309,499 General and administrative 2,286,794 1,945,741 Total $ 2,374,046 $ 2,255,240

WARRANTS (Tables)

WARRANTS (Tables)	12 Months Ended
	Apr. 30, 2021
Warrants and Rights Note Disclosure [Abstract]
Schedule of common stock warrants outstanding	The following table summarizes information about Common Stock warrants outstanding at April 30, 2021: Outstanding Exercisable Weighted Average Weighted Weighted Remaining Average Average Exercise Number Contractual Exercise Number Exercise Price Outstanding Life (years) Price Exercisable Price $1.00 500,000 3.1 $ 1.00 500,000 $ 1.00 $1.75 175,672 3.8 $ 1.75 175,672 $ 1.75 $3.00 7,427,196 3.5 $ 3.00 7,427,196 $ 3.00 $1.00 - $3.00 8,102,868 3.7 $ 2.85 8,102,868 $ 2.85
Schedule of estimated fair value of warrants granted	The estimated fair value of warrants granted during the year ended April 30, 2021 and 2020, were calculated using the Black-Scholes option-pricing model using the following assumptions: For the Year Ended April 30, 2021 2020 Common stock price $1.50 $1.50 Expected term (in years) 5.00 2.50 Volatility 103.70% 66% Risk-free interest rate 0.27% - 0.28% 1.52% Dividend yield 0.00% 0.00%

DESCRIPTION OF BUSINESS (Detail

DESCRIPTION OF BUSINESS (Details Narrative) - $ / shares	12 Months Ended
	Apr. 30, 2021	Apr. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of novel products	The Company’s primary focus is Alzheimer’s disease (“Alzheimer’s” or “AD”). With two current and future product candidates, Alzamend aims to bring treatments or cures to market at a reasonable cost as quickly as possible. The Company’s current pipeline consists of two novel therapeutic drug candidates (collectively, the “Technology”): (i) a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001 or LiProSal, through two royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., as licensor, and (ii) a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing exclusive worldwide license from the same licensor.
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001

LIQUIDITY, GOING CONCERN AND _2

LIQUIDITY, GOING CONCERN AND MANAGEMENT'S PLANS (Details Narrative) - USD ($)	Mar. 09, 2021	Mar. 31, 2021	Apr. 30, 2021	Apr. 30, 2020
Cash			$ 1,900,000
Accumulated deficit			(16,832,436)	$ (11,785,869)
Net loss			$ (5,046,567)	(4,410,236)
Value of common stock				$ 2,288,335
Common stock par value			$ 0.0001	$ 0.0001
Digital Power Lending [Member]
Common stock par value	$ 3
Cancellation convertible promissory note	2,666,667
Cancellation convertible promissory note value	$ 4,000,000
Cancellation convertible promissory note advance value	1,800,000
Cancellation convertible promissory note surrender value	$ 50,000
Securities Purchase Agreement [Member] | Digital Power Lending [Member]
Sale of common stock		6,666,667
Value of common stock		$ 10,000,000
Common stock par value		$ 1.50
Additional stock purchase		1,333,333
Purchase price		$ 2,000,000

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details) - shares		12 Months Ended
		Apr. 30, 2021	Apr. 30, 2020
Anti-dilutive securities		40,084,917	37,827,035
Stock Option [Member]
Anti-dilutive securities	[1]	16,750,000	16,175,000
Warrant [Member]
Anti-dilutive securities		8,102,868	6,652,035
Convertible Notes [Member]
Anti-dilutive securities		232,049
Series A Convertible Preferred Sock [Member]
Anti-dilutive securities		15,000,000	15,000,000
[1]	The Company has excluded 7,500,000 stock options, with an exercise price of $0.0004, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-13.

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2019
Cash and cash equivalents	$ 1,929,270	$ 90,285	$ 42,606
Stock Option [Member]
Exercise price (in dollars per share)	$ 0.0004
Number of stock excluded	7,500,000

NOTE RECEIVABLE, RELATED PART_2

NOTE RECEIVABLE, RELATED PARTY, NET (Details Narrative) - USD ($)	Apr. 30, 2019	Aug. 31, 2020	Apr. 30, 2021	Apr. 30, 2020	Apr. 10, 2018
Number of shares purchase				$ 2,288,335
Ault Life Sciences Fund, LLC (ALSF) [Member]
Principal amount			$ 14,883,295
Ault Life Sciences Fund, LLC (ALSF) [Member] | Securities Purchase Agreement [Member]
Principal amount		$ 50,000
Interest rate		8.00%
Number of shares purchase (in shares)	10,000,000
Number of shares purchase	$ 15,000,000
Share price (in dollar per shares)	$ 1.50
Ault Life Sciences Fund, LLC (ALSF) [Member] | Securities Purchase Agreement [Member] | Warrant [Member]
Number of shares purchase (in shares)		16,667
Number of warrants granted	5,000,000
Warrant terms	5 years	5 years
Exercise price (in dollars per share)	$ 3	$ 3
Avalanche International Corp (Avalanche) [Member] | Promissory Note [Member]
Principal amount	$ 100,915				$ 995,500
Interest rate	10.00%
Percentage of original issue discount	10.00%
Original issue discount			90,500
Contractual interest income			$ 1,706	$ 13,925

PREPAID EXPENSES AND OTHER CU_3

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)	Apr. 30, 2021	Apr. 30, 2020
Prepaid Expense and Other Assets [Abstract]
Prepaid consulting fees	$ 613,758	$ 1,513,602
Deferred offering costs	352,502
Interest receivable		77,153
Other prepaid expenses	850	15,850
Other receivables	16,210	16,210
Total prepaid expenses and other current assets	$ 983,320	$ 1,622,815

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Apr. 30, 2021	Apr. 30, 2020
Pre-tax loss:
Federal	$ (5,046,567)	$ (4,410,236)
Foreign
Total pre-tax income (loss)	$ (5,046,567)	$ (4,410,236)

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	Apr. 30, 2021	Apr. 30, 2020
Deferred income tax asset:
Net operating loss carryover	$ 3,360,381	$ 2,333,201
Other temporary differences	994,264	511,093
Total deferred tax asset	4,354,645	2,844,294
Valuation allowance	(4,354,645)	(2,844,294)
Deferred income tax asset, net of allowance

INCOME TAXES (Details 2)

INCOME TAXES (Details 2)	12 Months Ended
	Apr. 30, 2021	Apr. 30, 2020
Income Tax Disclosure [Abstract]
Tax benefit at U.S. Federal statutory tax rate	21.00%	21.00%
Increase (decrease) in tax rate resulting from:
Change in valuation allowance	(15.90%)	(20.90%)
Other	(5.10%)	(0.10%)
Effective tax rate	0.00%	0.00%

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	Apr. 30, 2021	Apr. 30, 2020
Valuation allowance	$ (4,354,645)	$ (2,844,294)
US Federal [Member]
Operating loss carryforwards	11,571,832
State and Local Jurisdiction [Member]
Operating loss carryforwards	$ 11,430,017

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details) - USD ($)	12 Months Ended
	Apr. 30, 2021	Apr. 30, 2020
Shares Available for Grant
Balance at beginning	575,000	4,290,000
Options granted	(125,000)	(3,750,000)
Options cancelled/forfeited		35,000
Increase to plan shares	10,000,000
Balance at end	10,450,000	575,000
Number of Options
Balance at beginning	19,425,000	15,710,000
Options granted	125,000	3,750,000
Options cancelled/forfeited		(35,000)
Balance at end	19,550,000	19,425,000
Options vested and expected to vest at end	17,550,000
Options exercisable at end	12,998,896
Weighted Average Exercise Price
Balance at beginning	$ 0.6964	$ 0.5228
Options granted	1.5000	1.4267
Options cancelled/forfeited		1
Balance at end	0.7195	$ 0.6964
Options vested and expected to vest at end	0.6675
Options exercisable at end	$ 0.4763
Weighted Average Remaining Contractual Life (years)
Weighted average remaining contractual life at beginning		7 years 6 months 4 days
Weighted average remaining contractual life at end	5 years 11 months 1 day	6 years 10 months 20 days
Options vested and expected to vest at end	6 years 5 months 19 days
Options exercisable at end	5 years 11 months 23 days
Aggregate Intrinsic Value
Aggregate intrinsic value at beginning	$ 15,609,500	$ 15,352,000
Aggregate intrinsic vale at end	35,159,500	$ 15,609,500
Options vested and expected to vest at end	32,159,500
Options exercisable at end	$ 26,306,032

STOCK-BASED COMPENSATION (Det_2

STOCK-BASED COMPENSATION (Details 1) - Employees And Consultants [Member]	12 Months Ended
	Apr. 30, 2021	Apr. 30, 2020
Dividend yield	0.00%	0.00%
Minimum [Member]
Expected term (in years)	3 years 6 months	2 years 6 months
Volatility	85.53%	65.80%
Risk-free interest rate	0.31%	1.52%
Maximum [Member]
Expected term (in years)	6 years 3 months	6 years 3 months
Volatility	100.09%	72.35%
Risk-free interest rate	0.51%	2.36%

STOCK-BASED COMPENSATION (Det_3

STOCK-BASED COMPENSATION (Details 2) - USD ($)	12 Months Ended
	Apr. 30, 2021	Apr. 30, 2020
Total	$ 2,374,046	$ 2,255,240
Research and Development [Member]
Total	87,252	309,499
General and Administrative [Member]
Total	$ 2,286,794	$ 1,945,741

STOCK-BASED COMPENSATION (Det_4

STOCK-BASED COMPENSATION (Details Narrative) - USD ($)	Nov. 26, 2019	Aug. 30, 2019	Jul. 10, 2019	Mar. 01, 2019	Apr. 30, 2016	Feb. 28, 2021	Nov. 30, 2018	Apr. 30, 2021	Apr. 30, 2020
Stock-based compensation								$ 2,374,046	$ 2,255,240
Options granted								125,000	3,750,000
Exercise price (in dollars per share)								$ 1.5000	$ 1.4267
Options vested and expected to vest								17,550,000
Weighted-average period vested and expected to vest at end								6 years 5 months 19 days
General and Administrative [Member]
Stock-based compensation								$ 2,286,794	$ 1,945,741
Unamortized Stock-Based Compensation [Member]
Options vested and expected to vest								3,700,000	6,000,000
Weighted-average period vested and expected to vest at end								1 year 10 months 24 days	2 years 7 months 6 days
Employee Stock Option [Member]
Stock-based compensation								$ 1,479,231	$ 1,293,915
Performance Contingent Stock Options [Member] | Chief Executive Officer [Member]
Options granted							2,000,000
Exercise price (in dollars per share)							$ 1
Performance Contingent Stock Options [Member] | Key Employees and Director [Member]
Terms of award	In the event any the stock price milestones are not achieved within three years, the unvested portion of the performance options will be reduced by 25%. Due to the significant risks and uncertainties associated with achieving the market-contingent awards, through April 30, 2021
Options granted	4,250,000
Exercise price (in dollars per share)	$ 1.50
Uplisting Agreement Compensation [Member] | Advisor [Member]
Expiration period			2 years
Stock-based compensation								$ 378,704	$ 303,724
Options granted			500,000
Exercise price (in dollars per share)			$ 1.3668
Placement Agent Compensation [Member] | Placement Agent [Member[
Options granted		500,000
Exercise price (in dollars per share)		$ 1.3668
Minimum [Member] | Performance Contingent Stock Options [Member]
Exercise price (in dollars per share)	15
Minimum [Member] | Performance Contingent Stock Options [Member] | General and Administrative [Member]
Stock-based compensation							$ 1,200,000
Maximum [Member] | Performance Contingent Stock Options [Member]
Exercise price (in dollars per share)	$ 40
2016 Stock Incentive Plan [Member]
Number of shares authorized for issuance					12,500,000
Additional number of shares available for issuance				7,500,000
2016 Stock Incentive Plan [Member] | Minimum [Member]
Expiration period					5 years
2016 Stock Incentive Plan [Member] | Maximum [Member]
Expiration period					10 years
2021 Stock Incentive Plan [Member]
Number of shares authorized for issuance						10,000,000
2021 Stock Incentive Plan [Member] | Maximum [Member]
Expiration period						10 years

WARRANTS (Details)

WARRANTS (Details)	Apr. 30, 2021$ / sharesshares
Exercise Price $1.00 [Member]
Exercse price (in dollars per share)	$ 1
Number warrant outstanding | shares	500,000
Weighted average remaining contractual life (years)	3 years 1 month 6 days
Warrant outstanding, weighted average exercise price (in dollars per share)	$ 1
Number of warrant exercisable | shares	500,000
Warrant exercisable, weighted average exercise price (in dollars per share)	$ 1
Exercise Price $1.75 [Member]
Exercse price (in dollars per share)	$ 1.75
Number warrant outstanding | shares	175,672
Weighted average remaining contractual life (years)	3 years 9 months 18 days
Warrant outstanding, weighted average exercise price (in dollars per share)	$ 1.75
Number of warrant exercisable | shares	175,672
Warrant exercisable, weighted average exercise price (in dollars per share)	$ 1.75
Exercise Price $3.00 [Member]
Exercse price (in dollars per share)	$ 3
Number warrant outstanding | shares	7,427,196
Weighted average remaining contractual life (years)	3 years 6 months
Warrant outstanding, weighted average exercise price (in dollars per share)	$ 3
Number of warrant exercisable | shares	7,427,196
Warrant exercisable, weighted average exercise price (in dollars per share)	$ 3
Exercise Price $1.00 - $3.00 [Member]
Number warrant outstanding | shares	8,102,868
Weighted average remaining contractual life (years)	3 years 8 months 12 days
Warrant outstanding, weighted average exercise price (in dollars per share)	$ 2.85
Number of warrant exercisable | shares	8,102,868
Warrant exercisable, weighted average exercise price (in dollars per share)	$ 2.85
Exercise Price $1.00 - $3.00 [Member] | Minimum [Member]
Exercse price (in dollars per share)	1
Exercise Price $1.00 - $3.00 [Member] | Maximum [Member]
Exercse price (in dollars per share)	$ 3

WARRANTS (Details 1)

WARRANTS (Details 1)	Apr. 30, 2021Number$ / shares	Apr. 30, 2020$ / shares
Risk-free interest rate [Member]
Warrants measurement input | Number	0.28
Warrant [Member]
Common stock price (in dollars per share) | $ / shares	$ 1.50	$ 1.50
Expected term (in years)	5 years	2 years 6 months
Warrant [Member] | Volatility [Member]
Warrants measurement input	1.0370	0.66
Warrant [Member] | Risk-free interest rate [Member]
Warrants measurement input		0.0152
Warrant [Member] | Risk-free interest rate [Member] | Maximum [Member]
Warrants measurement input	0.0027
Warrant [Member] | Risk-free interest rate [Member] | Minimum [Member]
Warrants measurement input	0.0028
Warrant [Member] | Dividend yield [Member]
Warrants measurement input	0	0

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - Warrant [Member] - USD ($)	Aug. 31, 2020	Aug. 11, 2020	Dec. 31, 2020	Oct. 31, 2019	Apr. 30, 2021
Principal amount	$ 50,000	$ 275,000	$ 44,000
Exercise price (in dollars per share)	$ 3	$ 3	$ 3	$ 3	$ 3
Number of stock repurchase	16,667	91,667	14,666	878,358	123,000
Placement Agent Warrants [Member]
Exercise price (in dollars per share)				$ 1.75
Offering Share				175,672
Stock conversion ratio				10.00%
Warrant term				5 years
Fair value of warrants					$ 95,467

OTHER RELATED PARTY TRANSACTI_2

OTHER RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Mar. 09, 2021	Apr. 30, 2019	Jan. 31, 2018	Aug. 17, 2017	Jun. 28, 2017	Mar. 31, 2021	Feb. 28, 2021	Dec. 31, 2020	Aug. 31, 2020	Apr. 30, 2021	Apr. 30, 2020
Common stock, par value (in dollars per share)										$ 0.0001	$ 0.0001
Ault Life Sciences Fund, LLC (ALSF) [Member]
Principal amount										$ 14,883,295
Short-term advances							$ 1,000,000	$ 800,000
Consulting Agreement [Member] | MCKEA and Spartan Capital Securities, LLC (Spartan) [Member]
Agreement term					5 years
Gross proceeds from private placement				$ 2,500,000
Number of shares transferred (in shares)			5,000,000	5,000,000
Securities Purchase Agreement [Member] | Ault Life Sciences Fund, LLC (ALSF) [Member]
Principal amount									$ 50,000
Number of shares purchase (in shares)		10,000,000
Interest rate									8.00%
Common stock, par value (in dollars per share)									$ 1.50
Share price (in dollar per shares)		$ 1.50
Securities Purchase Agreement [Member] | Ault Life Sciences Fund, LLC (ALSF) [Member] | Warrant [Member]
Warrant terms		5 years							5 years
Number of shares purchase (in shares)									16,667
Exercise price (in dollars per share)		$ 3							$ 3
Securities Purchase Agreement [Member] | Digital Power Lending (DPL) [Member]
Short-term advances										$ 1,800,000
Number of shares sold (in shares)						6,666,667
Number of shares sold						$ 10,000,000
Share price (in dollar per shares)						$ 1.50
Description of related party transaction	DPL paid $4 million, less the $1.8 million in advances and the surrender for cancellation of a $50,000 convertible promissory note held by Ault Global, each as described below, for an aggregate of 2,666,667 shares of Common Stock. Under the terms of the securities purchase agreement, DPL will purchase an additional (i) 1,333,333 shares of Common Stock if and upon approval by the FDA of our IND for our Phase Ia clinical trials for a purchase price of $2 million, and (ii) 2,666,667 shares of our Common Stock upon the completion of these Phase Ia clinical trials for a purchase price of $4 million.
Description of milestones						As of the date this Annual Report, the milestones related to additional funding have not been acheived. The Company further agreed to issue to DPL warrants to purchase a number of shares of Common Stock equal to 50% of the shares of Common Stock purchased under the securities purchase agreement at an exercise price of $3.00 per share. Finally, the Company agreed that for a period of 18 months following the date of the payment of the final tranche of $4 million, DPL will have the right to invest an additional $10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million as of the date of this Annual Report.

CONVERTIBLE NOTES (Details Narr

CONVERTIBLE NOTES (Details Narrative) - USD ($)	1 Months Ended			12 Months Ended
	Feb. 28, 2021	Dec. 31, 2020	Aug. 31, 2020	Apr. 30, 2021	Apr. 30, 2020
Number of shares purchase					$ 2,288,335
Common stock, par value (in dollars per share)				$ 0.0001	$ 0.0001
Debt discount				$ 124,046
Securities Purchase Agreement [Member] | Convertible Promissory Note [Member]
Debt discount				91,241
Unamortized debt discount				12,770
Securities Purchase Agreement [Member] | Convertible Promissory Note [Member] | Warrant [Member]
Debt discount				136,816
Original issue discount				$ 45,575
Securities Purchase Agreement [Member] | Institutional Investor [Member] | Convertible Promissory Note [Member]
Principal amount	$ 348,073	$ 44,000	$ 275,000
Number of shares purchase	$ 331,498	$ 40,000	$ 250,000
Interest rate	10.00%	8.00%	8.00%
Common stock, par value (in dollars per share)	$ 1.50	$ 1.50	$ 1.50
Exercise price (in dollars per share)		$ 3	$ 3
Securities Purchase Agreement [Member] | Institutional Investor [Member] | Convertible Promissory Note [Member] | Warrant [Member]
Warrant terms		5 years	5 years
Number of shares purchase (in shares)		14,667	91,667

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - Paycheck Protection Program Loan [Member] - USD ($)	1 Months Ended
	May 31, 2020	Dec. 31, 2020
Received forgiveness		$ 62,110
Loan proceeds	$ 62,110
Received forgiveness of accrued interest payable		$ 308
Description of loans and accrued interest forgivable terms	The loans and accrued interest are forgivable after the earlier of (i) 24 weeks after the loan disbursement date and (ii) December 31, 2020 as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels.

CONVERTIBLE NOTE - RELATED PA_2

CONVERTIBLE NOTE - RELATED PARTY (Details Narrative)	1 Months Ended
	Aug. 31, 2020USD ($)$ / sharesshares	Apr. 30, 2021USD ($)Number
Price Volatility [Member]
Estimated fair value of warrants | Number		103.7
Risk Free Interest Rate [Member]
Estimated fair value of warrants | Number		0.28
Convertible Promissory Note [Member]
Debt discount amount | $		$ 14,300
Convertible Promissory Note [Member] | Securities Purchase Agreement [Member] | AGH [Member]
Principal amount | $	$ 50,000
Interest rate on debt	8.00%
Warrant exercise price (in dollars per share) | $ / shares	$ 3
Warrant terms	5 years
Share price (in dollars per share) | $ / shares	$ 1.50
Convertible Promissory Note [Member] | Securities Purchase Agreement [Member] | Investor [Member]
Number of share repurchase | shares	16,667
Convertible Promissory Note [Member] | Price Volatility [Member]
Debt instrument measurement input		1.037
Convertible Promissory Note [Member] | Risk Free Interest Rate [Member]
Debt instrument measurement input		0.0028

EQUITY TRANSACTIONS (Details Na

EQUITY TRANSACTIONS (Details Narrative) - USD ($)	Mar. 09, 2021	Apr. 30, 2019	Mar. 31, 2021	Oct. 31, 2019	Apr. 30, 2021	Apr. 30, 2019	Dec. 31, 2020	Aug. 31, 2020	Aug. 11, 2020	Apr. 30, 2020	May 27, 2016
Preferred stock, authorized					10,000,000					10,000,000
Preferred stock, par value (in dollars per share)					$ 0.0001					$ 0.0001
Common stock, authorized before amendment to Certificate of Incorporation											150,000,000
Common stock, authorized					300,000,000					300,000,000	300,000,000
Warrant [Member]
Warrant terms					5 years					2 years 6 months
Exercise price (in dollars per share)				$ 3	$ 3		$ 3	$ 3	$ 3
ALSF [Member]
Shares purchase price		$ 15,000,000
Warrant terms		12 months				12 months
Securities Purchase Agreements [Member] | ALSF [Member]
Number of shares purchase		10,000,000
Shares purchase price		$ 15,000,000
Shares purchase price (in dollars per share)		$ 1.50
Securities Purchase Agreements [Member] | ALSF [Member] | Warrant [Member]
Number of shares purchase		5,000,000
Warrant terms		5 years				5 years
Exercise price (in dollars per share)		$ 3				$ 3
Securities Purchase Agreements [Member] | Digital Power Lending (DPL) [Member]
Percentage of shares entitled to receive			50.00%
Proceeds from sale of equity			$ 10,000,000
Number of shares issued			6,666,667
Shares issued price per share			$ 1.50
Exercise price (in dollars per share)			$ 3
Proceeds from related party	$ 4,000,000
Advance from related parties	$ 1,800,000
Description of purchase agreement terms			DPL will purchase an additional (i) 1,333,333 shares of Common Stock if and upon approval by the FDA of our IND for our Phase Ia clinical trials for a purchase price of $2 million, and (ii) 2,666,667 shares of our Common Stock upon the completion of these Phase Ia clinical trials for a purchase price of $4 million. The Company further agreed to issue to DPL warrants to purchase a number of shares of Common Stock equal to 50% of the shares of Common Stock purchased under the securities purchase agreement at an exercise price of $3.00 per share. Finally, the Company agreed that for a period of 18 months following the date of the payment of the final tranche of $4 million
Securities Purchase Agreements [Member] | Digital Power Lending (DPL) [Member] | Final Tranche [Member]
Proceeds from related party			$ 4,000,000
Additional right to invest			$ 10,000,000		$ 10,000,000
Securities Purchase Agreements [Member] | Ault Global [Member] | Convertible Promissory Note [Member]
Number of shares issued	2,666,667
Shares value surrender for cancellation	$ 50,000
Subscription Agreements (the "2019 Offering") [Member]
Number of stock unit purchase				1,756,726
Shares purchase price (in dollars per share)				$ 1.50
Description of each unit consists				Each unit consists of one (1) share of Common Stock and one (1) warrant to purchase one half (0.5) share of Common Stock. In aggregate, the 1,756,726 units represents 1,756,726 shares of Common Stock and 878,363 warrants with an exercise price of $3.00 per share for an aggregate purchase price of $2,635,089, or $1.50 per share.
Confidential Private Placement Memorandum (the "2019 PPM") [Member]
Proceeds from sale of equity						$ 2,239,826
Placement fees						$ 395,263
Confidential Private Placement Memorandum (the "2019 PPM") [Member] | Placement Agent [Member[
Number of shares issued					500,000
Payment of non-refundable fee					$ 25,000
Confidential Private Placement Memorandum (the "2019 PPM") [Member] | Placement Agent [Member[ | Placement Agent Warrants [Member]
Percentage of shares entitled to receive					10.00%
Warrant terms					5 years
Exercise price (in dollars per share)					$ 1.75
Confidential Private Placement Memorandum (the "2019 PPM") [Member] | Mr. Ault [Member]
Number of shares issued					10,000,000
Confidential Private Placement Memorandum (the "2019 PPM") [Member] | Stephan Jackman [Member]
Employment terms					2 years
Confidential Private Placement Memorandum (the "2019 PPM") [Member] | Advisor [Member] | Minimum [Member]
Gross proceeds					$ 1,000,000
Uplisting Agreement [Member] | Advisor [Member]
Proceeds from sale of equity					$ 475,000
Number of shares issued					500,000
Series A Convertible Preferred Stock [Member]
Preferred stock, authorized					8,640,000
Preferred stock, par value (in dollars per share)					$ 0.0001					$ 0.0001
Preferred stock, designated					1,360,000					1,360,000
Preferred stock, issued					750,000					750,000
Preferred stock, outstanding					750,000					750,000
Description of dividend rights					No dividend rights except as may be declared by the Board in its sole and absolute discretion, out of funds legally available for that purpose.
Preferred stock voting rights					Entitled to 50 non-cumulative votes per share on all matters presented to our stockholders for action.
Preferred stock terms of conversion					The right to convert their shares into shares of Common Stock at any time at a conversion rate equal to twenty (20) shares of Common Stock for every one (1) Series A Preferred Share.

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Jun. 17, 2021	May 31, 2021	Apr. 30, 2020
Number of shares issued for services, value			$ 808,379
Subsequent Event [Member] | Mr. William Horne [Member]
Number of shares issued for services, value		$ 50,000
Subsequent Event [Member] | Initial Public Offering [Member]
Number of shares issued in transaction	2,500,000
Price per share (in dollars per share)	$ 5
Proceeds from initial public offering	$ 14,400,000
Subsequent Event [Member] | Initial Public Offering [Member] | Mr. Ault [Member]
Description of conversion		The effectiveness of the initial public offering, and in consideration for (i) the conversion of 750 shares of our series A convertible preferred stock beneficially owned by Mr. Ault through Ault Life Sciences, Inc. into 15,000,000 shares of Common Stock, (ii) the extension of the maturity date of the note in the original principal amount of $15,000,000 issued to the Company by Ault Life Sciences Fund, LLC, an entity controlled by Mr. Ault, to December 31, 2023, and (iii) the retirement by Mr. Ault as a director and executive officer of the Company
Percentage of outstanding common shares		5.00%
Subsequent Event [Member] | Initial Public Offering [Member] | Mr. Ault [Member] | Consulting Agreement [Member]
Agreement term		5 years
Advisory and consulting services fees		$ 50,000
Subsequent Event [Member] | Over-Allotment Option [Member]
Number of shares issued in transaction	375,000
Price per share (in dollars per share)	$ 5